FDA approves Alzheimer’s drug, pushing drugmaker’s shares up |

Shares of Eisai Co. surged the most in more than three months after winning initial US regulatory clearance for lecanemab, the first treatment seen to slow the advance of brain-wasting Alzheimer’s disease.

Eisai shares jumped as much as 9.2 percent in Tokyo trading Tuesday, the most since Sept. 29 on an intraday basis. The stock had dropped 19 percent through Friday from a peak of ¥10,050 on December 5. Characterized by the presence of toxic brain deposits of a protein called amyloid, Alzheimer’s disease damages the minds and memories of some 6 million Americans. Lecanemab is among a series of drugs aimed at removing those deposits, and while it’s far from a cure, the companies recently found in a final-stage trial that it slowed cognitive decline by 27 percent over 18 months compared with a placebo in a late-stage trial.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA bares 20 adverse effects of kids’ syrupNearly 20 adverse drug reactions from Sangobion Kids, an iron syrup supplement for children, were reported more than two weeks after the Food and Drug Administration issued a recall notice due to toxic substance contamination.
Source: inquirerdotnet - 🏆 3. / 86 Read more »

FDA bares 20 adverse effects of kids’ syrupNearly 20 adverse drug reactions from Sangobion Kids, an iron syrup supplement for children, were reported more than two weeks after the Food and Drug Administration (FDA) issued a recall notice
Source: cebudailynews - 🏆 8. / 71 Read more »